Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), announced the resumption of testing of hydroxychloroquine in the treatment of COVID-19. Speaking at a briefing in Geneva, he said there was no reason to change the order of these tests.
The head of the WHO stressed that “leading researchers” will be informed about the “resumption of trials of hydroxychloroquine.”
He recalled that last week it was decided to “establish a temporary pause in the trials of hydroxychloroquine due to concerns about the safety of this drug.” Members of the Committee monitoring the tests reviewed the issue and” based on the available mortality data, made a recommendation that there is no reason to modify the test report, ” Tedros Adanom Ghebreyesus added.
On Monday, WHO informed that a decision to continue testing might be made soon.
Hydroxychloroquine is a drug against malaria that has recently been used in some countries to treat patients with coronavirus. A few days ago, who suspended clinical trials of this drug, because, according to some doctors, the use of hydroxychloroquine not only does not help in the treatment of coronavirus but also can be dangerous for the health of patients due to the side effects it causes. In March, US President Donald Trump advocated the widespread use of this drug for the treatment of COVID-19. Later, he said that he regularly takes hydroxychloroquine to prevent coronavirus.
The World Health Organization (WHO) does not have information about the existence of a drug that would significantly reduce the death rate of patients with coronavirus. This was stated on Wednesday at a briefing by the WHO chief scientific officer Soumya Swaminathan.
According to her, finding a cure is a priority for the organization. “Everything possible is being done, comparative clinical trials are being conducted to get data as soon as possible,” the expert stressed. “And who strongly welcomes the continuation of such trials to find a drug that reduces the death rate and severity of the disease.” However, at the moment, “there is no evidence that there is a drug that significantly reduces the mortality of patients with coronavirus,” Swaminathan said.